Stefano Aliberti to Community-Acquired Infections
This is a "connection" page, showing publications Stefano Aliberti has written about Community-Acquired Infections.
Connection Strength
0.919
-
Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulm Pharmacol Ther. 2017 08; 45:191-201.
Score: 0.277
-
Never Let a Good Crisis Go to Waste. Chest. 2021 03; 159(3):917-919.
Score: 0.090
-
Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia. Respirology. 2020 05; 25(5):543-551.
Score: 0.080
-
International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. J Infect. 2019 10; 79(4):300-311.
Score: 0.080
-
Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. BMC Infect Dis. 2018 Dec 18; 18(1):677.
Score: 0.077
-
An international perspective on hospitalized patients with viral community-acquired pneumonia. Eur J Intern Med. 2019 02; 60:54-70.
Score: 0.076
-
Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. Respir Res. 2018 Oct 23; 19(1):205.
Score: 0.076
-
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018 08; 52(2).
Score: 0.075
-
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. Eur Respir J. 2017 09; 50(3).
Score: 0.070
-
An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opin Pharmacother. 2017 Jul; 18(10):973-988.
Score: 0.017